Form 4: Sage Therapeutics Executive Michael Quirk Reports Stock Transactions Following PSU Vesting

Michael Quirk, Chief Scientific Officer of Sage Therapeutics, reports acquisition and disposal of common stock following the vesting of Performance Restricted Stock Units (PSUs).

Summary

• Michael Quirk, Chief Scientific Officer of Sage Therapeutics, filed a Form 4 detailing changes in beneficial ownership.
• The transactions involve the acquisition of 933 shares and 1,269 shares of common stock on April 10, 2025, due to the vesting of Performance Restricted Stock Units (PSUs).
• These PSUs were granted on February 11, 2022, and October 3, 2022, respectively, and vested upon the achievement of certain milestones.
• Simultaneously, 312 and 424 shares were disposed of to cover tax obligations at a price of $6.91 per share.
• Following these transactions, Quirk directly owns 30,574 shares of Sage Therapeutics common stock.

Sentiment

Score: 6

Explanation: The document is neutral, reporting routine transactions related to executive compensation. The vesting of PSUs suggests achievement of performance milestones, which is mildly positive.

Positives

• The vesting of PSUs indicates the achievement of certain performance milestones, which could be viewed positively.

Negatives

• The disposal of shares to cover tax obligations, while standard, represents a slight reduction in Quirk's holdings.

Risks

• There are no specific risks mentioned in this document.
• However, any potential risks would be related to the company's overall performance and stock volatility.

Future Outlook

The document does not contain any specific forward-looking statements.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency regarding insider transactions, allowing investors to monitor the actions of company executives and directors.

Comparison to Industry Standards

• Form 4 filings are standard practice across all publicly traded companies and are comparable in format and content.
• The vesting of PSUs is a common form of executive compensation, aligning management's interests with those of shareholders.

Stakeholder Impact

• The transactions have a minimal direct impact on stakeholders.
• However, transparency in insider transactions is important for maintaining investor confidence.

Key Dates

Keywords

Form 4, Sage Therapeutics, Michael Quirk, PSU, Stock, Beneficial Ownership, Vesting